Truist analyst David MacDonald lowered the firm’s price target on Labcorp to $275 from $285 but keeps a Buy rating on the shares. The analyst cites the company’s Q1 earnings miss but also notes that the COVID pandemic further highlighted the key role clinical labs play in clinical decision making. Truist contends that Labcorp boasts significant scale, a diverse service offering and is uniquely positioned in the areas of personalized medicine and potential risk-based reimbursement systems.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LH:
- Labcorp price target lowered to $240 from $265 at Deutsche Bank
- Labcorp price target lowered to $235 from $260 at Citi
- Labcorp raises FY23 adjusted EPS view $16.25-$17.75 from $16.00-$18.00
- Labcorp reports Q1 adjusted EPS $3.82, consensus $3.96
- Labcorp Announces 2023 First Quarter Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue